Pharmacy group
Loading network profile…
Pharmax (UK) LTD operates 5 NHS pharmacies. Dispensed 362k NHS items in the last 12 months, up 175.4% on the prior year. Estimated annual NHS income from dispensing and advanced services is around £1.2m. Deeply engaged with advanced services — nearly every branch is active, averaging 4.8 of 6 service lines. Operates 1 distance-selling pharmacy. The parent entity was only incorporated in 2023 — consistent with a recent acquisition vehicle.
A step-change usually marks an acquisition; a steady slope is organic trade. The Pharmacy First launch in January 2024 shows up across most groups.
Parsed from Pharmax (UK) LTD’s iXBRL-tagged filed accounts at Companies House. Values reflect the consolidated group figure where the filing is a group account. “—” means the figure was absent or filleted out of that year’s filing (smaller companies can omit P&L line items when filing abridged accounts). NHS dispensing revenue is included in these totals but cannot be separated from private / over-the-counter income at Companies House granularity — see the estimated NHS income panel for the split.
Each cell is one month. Darker cells mean more branches joined the network that month. Evenly-spaced light cells suggest organic growth or absorption by transfer; concentrated hot cells mark discrete acquisitions.
100-hour contracts carry higher opening-hour commitments for a higher core NHS fee. Distance-selling pharmacies fulfil prescriptions by post only — no walk-in customers.
Pharmax (UK) LTD is strongly over-indexed to deprived communities (+30pp vs a uniform national distribution). National baseline: exactly 30% of LSOAs sit in the most-deprived third, so that's the neutral line.
Least-deprived third: 20% · middle: 20%
Each coloured segment is one of the ten IMD deciles (segment widths scale with branch counts). Red = most-deprived communities; green = least-deprived. A heavy red-weighted bar reads as “serves deprived communities” — a meaningful operator identity in a sector where historical contract allocation concentrated pharmacies in low-income areas.
Each sparkline shows one branch's 12-month items trend. The percentage is the six-month change (last six vs prior six months); it's coloured green when the branch is growing by 3%+, red when declining by 3%+, neutral otherwise. Shapes that cluster tightly suggest a homogeneous chain; wide variation points to an acquired portfolio of independents. Click any card for its profile.
Each dot is one branch. The vertical line is the median 12-month items in this network; the horizontal line is flat (0%) trend. Quadrants are descriptive, not judgemental: a smaller-volume branch can be entirely appropriate where it serves a small or remote population. Commissioners and operators typically look at the lower-left quadrant as an early-warning area. Click any dot for the branch profile. 1 branch with ≥95% change — typically closed, transferred, or newly onboarded within the window — excluded from the plot so the main cluster is readable.
Each cell is the branch's year-on-year % items change for that month — red for decline, stone for flat, green for growth, capped at ±25%. A branch that turns red and stays red is a genuine contractor; a stone band is stable; an intermittent amber-to-green ramp signals recovery. Rows are ordered by 12-month volume — the right-hand number is items dispensed in the last 12 months, coloured red/green by the branch's 6-month trend so growth and decline are visible at both granularities.
Half of Pharmax (UK) LTD’s 5 reporting branches sit above the 47th national percentile for combined service engagement (NMS, Pharmacy First, BP, DMS, contraception, flu per 1,000 items). 2 branches beat the national median; 3 sit below.
Long-running appointments suggest a stable owner-operator. A cluster of resignations or a short director pattern can indicate a recent change in control, a restructure, or onboarding of external investors.
| # | Location | ICB | 12-month trend | Items (12m) | 6-mo Δ | Services |
|---|---|---|---|---|---|---|
| 1 | Kent · DA14 6EH | South East London ICB | 103.3k | +22% | 5 / 6 | |
| 2 | London · SE17 3NH | South East London ICB | 81.7k | +3% | 6 |
Group identity reconciled from NHSBSA Contractor Details using legal-entity name, enriched with Companies House registry data for the top 100 corporate groups. Dispensing aggregated across every branch currently owned by the group. Officer tenure and SIC codes sourced live from Companies House under Crown Copyright.
Estimate derived from published NHS fee rates: £2.85/item (SAF + professional fee), £28/NMS, £35/DMS, £17/Pharmacy First, £15/BP check, £18/contraception consultation; flu uses actual £ fees published per dose. Category M reimbursement, establishment payment, transitional payment, PQS banding and the £1,000 Pharmacy First monthly fixed fee are all excluded. Private and locally-commissioned income is not included.
Emerald shading is national pharmacy density; amber outlines flag hexes containing a Pharmax (UK) LTD branch. Lets you read regional strategy at a glance — clustered around a few cities, broadly distributed, or concentrated in one corner of the country.
| 3 | DA14 5DP | South East London ICB | 76.9k | +562% | 2 / 6 DSP |
| 4 | Kent · DA5 1LQ | South East London ICB | 57.8k | -3% | 6 / 6 |
| 5 | Kent · BR5 4AD | South East London ICB | 42.5k | +12% | 5 / 6 |